4-甲基呋喃-3-甲胺盐酸盐 | 321392-83-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-甲基呋喃-3-甲胺盐酸盐
• 中文别名: [(4-甲基-1,2,5-恶二唑-3-基)甲基]胺盐酸盐；C-4-甲基-3-恶二唑甲胺
• 英文名称: 3-aminomethyl-4-methyl-1,2,5-oxadiazole
• 英文别名: (4-Methyl-1,2,5-oxadiazol-3-yl)methanamine
• CAS: 321392-83-0
• 化学式: C₄H₇N₃O
• mdl: MFCD07800291
• 分子量: 113.119
• InChiKey: YKTPXKSUWIQBML-UHFFFAOYSA-N

物化性质

• 密度：
  1.191

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-甲基呋喃-3-甲胺盐酸盐 、 2-(5-chloro-2-methyl-1H-triazolo[4,5-b]pyrazin-6-ylidene)propanedinitrile 在 三乙胺 作用下， 以 乙醇 、 苯 为溶剂， 反应 2.0h， 以95%的产率得到6-Amino-2-methyl-5-(4-methyl-furazan-3-ylmethyl)-2,5-dihydro-1,2,3,4,5,8-hexaaza-s-indacene-7-carbonitrile
  参考文献：
  名称：

  Facile and general synthesis of pyrrolo[2,3-b]pyrazines via 2-(dicyanoylidene)-3-halopyrazines

  摘要：

  DOI：

  10.1070/mc2001v011n04abeh001452

文献信息

• Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones
  作者：Elise Isabel、Renee Aspiotis、W. Cameron Black、John Colucci、Réjean Fortin、André Giroux、Erich L. Grimm、Yongxin Han、Christophe Mellon、Donald W. Nicholson、Dita M. Rasper、Johanne Renaud、Sophie Roy、John Tam、Paul Tawa、John P. Vaillancourt、Steven Xanthoudakis、Robert J. Zamboni

  DOI：10.1016/j.bmcl.2006.12.110

  日期：2007.3

  protease that mediates apoptotic cell death. Its inhibition may have an important impact on the treatment of several degenerative diseases. Here we report the synthesis of reversible inhibitors via a solid-support palladium-catalyzed amination of 3-bromopyrazinones and the discovery of a pan-caspase reversible inhibitor.

  Caspase-3是半胱氨酸蛋白酶，介导凋亡的细胞死亡。它的抑制作用可能对几种退行性疾病的治疗产生重要影响。在这里，我们报告通过固相支持钯催化的3-溴吡嗪酮的胺化反应合成可逆抑制剂，以及泛半胱天冬酶可逆抑制剂的发现。
• Synthesis, biological evaluation and in silico modeling of novel integrase strand transfer inhibitors (INSTIs)
  作者：Andrey A. Ivashchenko、Yan A. Ivanenkov、Angela G. Koryakova、Ruben N. Karapetian、Oleg D. Mitkin、Vladimir A. Aladinskiy、Dmitry V. Kravchenko、Nikolai P. Savchuk、Alexander V. Ivashchenko

  DOI：10.1016/j.ejmech.2020.112064

  日期：2020.3

  the well-studied halogen-substituted benzyl fragment. With the focus on the mentioned diversity point, a medium-sized library of compounds was selected for synthesis. A biological study revealed that many molecules were highly active INSTIs (EC50 < 10 nM). Two compounds 14} and 126} demonstrated picomolar antiviral activity that was comparable with CAB and were more active than DTG and BIC. Molecular

  尽管目前有相对广泛的治疗选择可用于治疗HIV / AIDS，但它仍然是最严重和最致命的疾病之一，并且死亡率很高。整合酶链转移抑制剂（INSTI），例如FDA批准的dolutegravir（DTG），bictegravir（BIC）和CABo​​tegravir（CAB），最近已作为标准的高效抗逆转录病毒疗法（HAART）方案中的五种主要成分之一获得最有益的临床结果。在本文中，我们描述了包含杂芳族生物等位取代而不是经过充分研究的卤素取代的苄基片段的新型INSTI的组合酰胺合成，生物学评估和计算机模拟。着眼于上述多样性点，选择了中等大小的化合物文库进行合成。一项生物学研究表明，许多分子是高活性的INSTI（EC50 <10 nM）。两种化合物1 4}和1 26}表现出与CAB相当的皮摩尔抗病毒活性，并且比DTG和BIC更具活性。进行了分子对接研究以评估化合物在HIV-1 IN活性位点的结合模式。在大鼠中，铅化合物1
• Thioxanthine derivatives and their use as inhibitors of MPO
  申请人：AstraZeneca AB

  公开号：US08026244B2

  公开（公告）日：2011-09-27

  There are disclosed novel compounds of Formula (I) wherein L, R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.

  本发明涉及一种新型化合物的公开，其化学式为(I)，其中L、R1、X和Y如规范中所定义，并且其药学上可接受的盐；以及它们的制备方法、含有它们的组合物和它们在治疗中的应用。这些化合物是MPO酶的抑制剂，因此特别适用于治疗或预防神经炎症性疾病、心脏和脑血管动脉粥样硬化性疾病、周围动脉疾病和呼吸系统疾病。
• Thioxanthine Derivatives and Their Use as Inhibitors of MPO
  申请人：Tiden Anna-Karin

  公开号：US20090149475A1

  公开（公告）日：2009-06-11

  There are disclosed novel compounds of Formula (I) wherein L, R 1 , X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.

  本发明公开了新的化合物式（I），其中L、R1、X和Y如规范中所定义，并且其药学上可接受的盐；以及其制备方法、含有它们的组合物和它们在治疗中的应用。这些化合物是MPO酶的抑制剂，因此在神经炎症性疾病、心血管和脑血管动脉粥样硬化性疾病、周围动脉疾病和呼吸系统疾病的治疗或预防中特别有用。
• Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors
  作者：Yongxin Han、André Giroux、John Colucci、Christopher I. Bayly、Daniel J. Mckay、Sophie Roy、Steve Xanthoudakis、John Vaillancourt、Dita M. Rasper、John Tam、Paul Tawa、Donald W. Nicholson、Robert J. Zamboni

  DOI：10.1016/j.bmcl.2004.12.006

  日期：2005.2

  The iterative process for the discovery of a series of pyrazinone mono-amides as potent, selective and reversible non-peptide caspase-3 inhibitors (e.g., M826 and M867) is reported. These compounds display potent anti apoptotic activities in a number of cell based systems in vitro as well as in several animal models in vivo. (C) 2004 Elsevier Ltd. All rights reserved.